- Wednesday, October 10
- 12:45 PM - 2:00 PM
- Room 26, Level 2
Elevated triglyceride (TG) levels are associated with significantly increased cardiovascular mortality and morbidity. While statins remain the mainstay of dyslipidemia, a large residual risk remains in patients treated to LDL-C goals. This program will be presented by distinguished experts in the field to provide the healthcare professional managing dyslipidemia with a clinical background of the problem, methods to screen and diagnose, evidence-based strategies, and clinical treatment plans to improve outcomes of their patients.
Discuss the etiology, diagnosis (including non-HDL-C), and risk assessment of hypertriglyceridemia (HTG), and the impact of residual CVD risk that remains beyond statin therapy, including patients with HTG
Summarize the clinical and genetic evidence for the observational and causal association between elevated triglycerides (TG) / TG-rich lipoproteins and atherosclerosis
Apply evidence-based guidelines to lifestyle and therapeutic approaches for managing patients with elevated non-HDL-C and HTG
Describe the anti-atherosclerotic / anti-inflammatory properties of TG-lowering agents, with a focus on prescription omega-3 fatty acids, and biologic/clinical characteristics of EPA and DHA
Relate the current status and recommendations on omega-3 FA dietary supplementation; Increase competency to formulate an action plan for managing elevated non-HDL-C and HTG, taking into account overall therapeutic value to achieve individualized patient goals
Download a PDF of Presented Slides.DOWNLOAD
Eliot A. Brinton, MD, is president of the Utah Lipid Center in Salt Lake City, Utah. He is past president of the American Board of Clinical Lipidology and of the Pacific Chapter of the National Lipid Association and is a member of the Board of Direct...